Finoriq research workspace
ABVC BIOPHARMA, INC. (ABVC) SEC Filings & Filing Highlights
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical. Review ABVC SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
- Company
- ABVC BIOPHARMA, INC. (ABVC)
- Ticker
- ABVC
- Market Cap
- $32.5M
- Latest Price
- $1.2499
- Industry
- Biotech & Pharma
ABVC BIOPHARMA, INC. (ABVC) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ABVC BIOPHARMA, INC. (ABVC).
| Event | Form | Date |
|---|---|---|
| Changes in Registrant’s Certifying AccountantChanges in Registrant’s Certifying Accountant | 8-K4.01 | 2026-07-02 |
| We are filing this Current Report on Form 8-K to disclose the voting results from the Annual Me...On March 26, 2026, ABVC BioPharma, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). At the Annual... | 8-K5.07 | 2026-03-27 |
| or a Related Audit Report or Completed Interim Review. On February 25, 2026, the Board of Direc...or a Related Audit Report or Completed Interim Review. On February 25, 2026, the Board of Directors (the “Board”) of ABVC Biopharma, Inc. (... | 8-K4.02 | 2026-03-03 |
| ABVC BioPharma Reports 2025 Form 10-KTotal Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model | 8-K2.02 | 2026-03-03 |
| ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 | 8-K2.02 | 2025-11-03 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.